Biosimilar infliximab for Behçet's syndrome: a case series.

Tarih
2019
Yazar
Hatemi, G.
Fresko, I.
Ozyazgan, Y.
Kutlubay, Z.
Mat, M. C.
Yurdakul, S.
Siva, A.
Hamuryudan, V.
Ucar, Didar
Dincses, E.
Esatoglu, S. N.
Ozguler, Y.
Uygunoglu, U.
Seyahi, E.
Melikoglu, M.
Üst veri
Tüm öğe kaydını göster
Özet
Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.
Bağlantı
http://hdl.handle.net/20.500.12627/59819
Koleksiyonlar